Brief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
13/10/2026 13:09
BRIEF-iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study Oct 13 (Reuters) - iBio Inc IBIO.O:
IBIO - IBIO-610 PLUS SEMAGLUTIDE PRESERVES LEAN MASS IN EIGHT-WEEK OBESE NHP STUDY
IBIO - IBIO-610 DEMONSTRATES 97% REDUCTION IN ACTIVE ACTIVIN E AT WEEK 8 IN NHP STUDY
IBIO - EXPECTS TO START FIRST-IN-HUMAN TRIALS OF IBIO-610 IN FIRST HALF OF 2027
IBIO - FAT ACCOUNTED FOR 93% OF WEIGHT LOST WITH IBIO-610 PLUS SEMAGLUTIDE AT WEEK 8
Source text: ID:nGNX2pgrTB
Further company coverage: IBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on iBio
See all newsBrief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron